09Jan/14

Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies – Genetic Engineering News

Antibodies

Lilly Licenses Zymeworks Technology to Develop Bi-specific Antibodies
Genetic Engineering News
Zymeworks has entered into a worldwide licensing and collaboration agreement with ImClone Systems, a wholly owned subsidiary of Eli Lilly, to develop a number of bi-specific antibody oncology therapeutics using Zymeworks’ Azymetric™ platform.
Zymeworks Announces $15.0 Million Private Placement Financing to Advance …The Herald | HeraldOnline.com (press release)
Zymeworks, ImClone Systems partner to develop novel bi-specific antibody …News-Medical.net

all 14 news articles »
08Jan/14

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies – DailyFinance

Antibodies

Drug Discovery & Development

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies
DailyFinance
Seattle Genetics is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer. Now AbbVie has agreed to pay $25 million to gain …
Seattle Gentics-AbbVie Deal ExpandedZacks.com
Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with …Wall Street Journal
Seattle Genetics and AbbVie Broaden PartnershipPharmaceutical Processing

all 20 news articles »
08Jan/14

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies – Motley Fool

Antibodies

Drug Discovery & Development

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies
Motley Fool
Seattle Genetics (NASDAQ: SGEN ) is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer. Now AbbVie (NYSE: ABBV ) has …
Seattle Gentics-AbbVie Deal ExpandedZacks.com
Seattle Genetics, AbbVie Broaden PartnershipDrug Discovery & Development

all 20 news articles »
08Jan/14

New Method for Efficiently Transporting Antibodies Across the Blood-Brain Barrier – Science Daily (press release)

Antibodies

New Method for Efficiently Transporting Antibodies Across the Blood-Brain Barrier
Science Daily (press release)
8, 2014 — Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models.
Roche “brain shuttle” technology offers Alzheimer’s hopeReuters

all 10 news articles »
08Jan/14

Roche reports new method for efficiently transporting antibodies across the … – EurekAlert (press release)

Antibodies

The Malay Mail Online

Roche reports new method for efficiently transporting antibodies across the …
EurekAlert (press release)
Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models1. Roche …
Roche “brain shuttle” technology offers Alzheimer’s hopeReuters

all 14 news articles »
08Jan/14

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies – Xconomy

Antibodies

Drug Discovery & Development

Seattle Genetics Nabs $25M More From AbbVie for Souped Up Antibodies
Xconomy
Seattle Genetics is best known for its one successful marketed cancer drug, but it has been busy working behind the scenes for years on new technologies for making souped-up antibodies against cancer. Now AbbVie has agreed to pay $25 million to gain …
Seattle Genetics Further Expands Antibody-Drug Conjugate Collaboration with …Wall Street Journal
Seattle Genetics, AbbVie Broaden PartnershipDrug Discovery & Development

all 9 news articles »
08Jan/14

Memorial Sloan-Kettering to use Sutro's technology for new bispecific antibodies – Pharmaceutical Business Review

Antibodies

Memorial Sloan-Kettering to use Sutro’s technology for new bispecific antibodies
Pharmaceutical Business Review
PBR Staff Writer Published 08 January 2014. US-based biopharmaceutical firm Sutro Biopharma has entered into a collaboration agreement with Memorial Sloan-Kettering Cancer Center to produce bispecific antibodies for the treatment of neuroblastoma.